Bayesian Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bayesian Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-19,400	Closed	-$151K	–	748
2023 Q3	$151K	Buy	+19,400	New	+$190K	0.02%	577
2023 Q2	–	Sell	-22,000	Closed	-$241K	–	791
2023 Q1	$241K	Buy	+22,000	New	+$194K	0.03%	566
2022 Q3	–	Sell	-32,183	Closed	-$323K	–	697
2022 Q2	$323K	Buy	+32,183	New	+$360K	0.06%	455
2018 Q2	–	Sell	-16,300	Closed	-$85K	–	589
2018 Q1	$85K	Buy	+16,300	New	+$87.2K	0.02%	535

Other funds holding AUPH

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bayesian Capital Management's AUPH Position: Q4 2023 in Review

Bayesian Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2023, closing a stake of 19,400 shares — an estimated $151K sold.

Bayesian Capital Management first reported a position in AUPH in Q1 2018 and held it in 4 quarters. The position peaked at $323K in Q2 2022. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2023.

Bayesian Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Bayesian Capital Management sold 19,400 Aurinia Pharmaceuticals shares in Q4 2023, an estimated $151K.
Bayesian Capital Management first reported a position in Aurinia Pharmaceuticals in Q1 2018 and held it in 4 quarters.
Bayesian Capital Management's Aurinia Pharmaceuticals position peaked at $323K in Q2 2022.
191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.